Clostridia pp 265-292 | Cite as

Toxigenic Clostridia

  • Clifford C. Shone
  • Peter Hambleton
Part of the Biotechnology Handbooks book series (BTHA, volume 3)


The members of the genus Clostridium elaborate a wide range of exopro-teins, many of which may function as virulence factors since many strains within the genus are pathogenic to both man and animals. Since the spores of Clostridia are widely distributed in the environment, contaminating soil, dust, feces, insects, raw foodstuffs, and even cooked foods, it is not surprising that these organisms are frequently found in association with diseases arising primarily from contamination of wounds and foodstuffs.


Botulinum Toxin Clostridium Perfringens Botulinum Neurotoxin Tetanus Toxin Clostridium Botulinum 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agui, T., Syuto, B., Oguma, K., Iida, H., and Kubo, S., 1985, Binding of Clostridium botulinum type C to rat brain synaptosomes, J. Biochem. 94:521–527.Google Scholar
  2. Aktories, K., Barmann, M., Ohishi, I., Tsuyama, S., Jakobs, K. and Habermann, E., 1986, Botulinum C2 toxin ADP-ribosylates actin, Nature 322:390–392.PubMedGoogle Scholar
  3. Alouf, J. E. and Jolivet-Reynaud, C. 1981, Purification and characterization of Clostridium perfringens delta toxin, Infect. Immun. 31:536–546.PubMedGoogle Scholar
  4. Arnon, S., 1981, Infant botulism, pathogenesis, clinical aspects and relation to crib death, in: Biomedical Aspects of Botulism (G. E. Lewis Jr., ed.), Academic Press, New York, pp. 331–345.Google Scholar
  5. Arseculeratne, S. N., Pannabokke, R. G., and Wijesundera, S., 1969, The toxins responsible for the lesions of Clostridium sordelli gas gangrene, J. Med. Microbiol. 2:37–53.PubMedGoogle Scholar
  6. Banno, Y. T., Kobayashi, T., Kono, H., Watanabe, K., Ueno, K., and Nozawa, Y., 1984, Biochemical characterization and biologic action of two toxins (D1 and D2) from Clostridium difficile, Rev. Infect. Dis. 6:S11–S20.Google Scholar
  7. Bartlett, J. G., 1979, Antibiotic associated pseudo-membranous colitis, Rev. Infect. Diseases 1:530–539.Google Scholar
  8. Bartlett, J. G., 1983, Pseudomembranous colitis in: Human intestinal microflora in health and disease (D. J. Hentges, ed.), Academic Press, New York, pp. 447–479.Google Scholar
  9. Bizzini, B., 1979, Tetanus toxin, Microbiol. Rev. 43:224–240.PubMedGoogle Scholar
  10. Black, J. D., and Dolly, J. O., 1986, Interaction of 125I-labeled botulinum neurotoxins with nerve terminals, J. Cell. Biol. 103:521–534.PubMedGoogle Scholar
  11. Bleck, T. P., 1986, Pharmacology of tetanus, Clin. Neuropharmacol., 9:103–120.PubMedGoogle Scholar
  12. Bolton, R. P., and Thomas, D. F. M., 1986, Pseudomembranous colitis in children and adults, Br. J. Hosp.Med. 35:37–41.PubMedGoogle Scholar
  13. Boriello, S. P., 1985a, Clostridia in Gastrointestinal disease, CRC, Boca Raton.Google Scholar
  14. Boriello, S. P., 1985b, Newly described clostridial diseases of the gastrointestinal tract: Clostridium perfringens enterotoxin-associated diarrhoea and neutropenic enterocolitis due to Clostridium septicum, in: Clostridia in Gastrointestinal Disease (S. P. Boriello, ed.), CRC, Boca Raton pp. 224–229.Google Scholar
  15. Boriello, S. P. and Carman, R. J., 1985, Clostridial diseases of the gastrointestinal tract in animals, in: Clostridia in Gastrointestinal Disease (S. P. Boriello, ed.), CRC, Boca Raton, pp. 195–221.Google Scholar
  16. Boriello, S. P., and Larson, H. E., 1985, Pseudomembranous and antibiotic-associated colitis, in: Clostridia in Gastrointestinal Disease (S. P. Boriello, ed.), CRC, Boca Raton, pp. 145–164.Google Scholar
  17. Boyd, N. A., Walker, P. D., and Thomson, R. O., 1972, The prevention of experimental Clostridium novyi gas gangrene in high velocity missile wounds by passive immunization, J. Med. Microbiol. 5:459–465.PubMedGoogle Scholar
  18. Chang, T. W., Gorbach, S. C., and Bartlett, J. B., 1978, Neutralization of Clostridium difficile toxin by Clostridium sordelli antitoxin, Infect. Immun. 22:418–422.PubMedGoogle Scholar
  19. Christie, A. B., 1980, Infectious diseases: epidemiology and clinical practice 3rd ed. Churchill Livingstone, New York.Google Scholar
  20. DasGupta, B. R., 1981, Structure-function relation of botulinum toxins, in: Biomedical Aspects of Botulism (G. E. Lewis Jr., ed.), Academic Press, New York, pp. 1–19.Google Scholar
  21. DasGupta, B. R., and Sugiyama, H., 1972, A common subunit structure in Clostridium botulinum type A, B and E toxins, Biochem. Biophys. Res. Commun. 48:108–112.PubMedGoogle Scholar
  22. Dolly, J. O., Black, J. D., Williams, R. S., and Melling, J., 1984, Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization, Nature 307:457–460.PubMedGoogle Scholar
  23. Dreyer, A. S. F., and John, C., 1981, At least three sequential steps are involved in tetanus toxin-induced block of neuromuscular transmission, Naun. Schmiedeberg’s Arch. Pharmacol. 317:326–330.Google Scholar
  24. Duncan, C. L., Strong, D. H., and Sebald, M., 1972, Sporulation and enterotoxin production by a mutant of Clostridium perfringens, J. Bacteriol. 110:378–391.PubMedGoogle Scholar
  25. Editorial, 1987, Clostridium septicum and neutropenic enterocolitis, Lancet 2:608.Google Scholar
  26. Eisel, U., Jarausch, W., Goretzki, K., Henschen, A., Engels, J., Weiler, U., Hudel, M., Habermann, E., and Niemann, H., 1986, Tetanus toxin: Primary structure, expression in E. coli, and homology with botulinum toxins, EMBO J. 5:2495–2502.PubMedGoogle Scholar
  27. Elston, J. S., 1988, Botulinum toxin therapy for involuntary eye movement, Eye 2:12–15.PubMedGoogle Scholar
  28. Elston, J. S., and Ross-Russell, R. W., 1985, Effect of treatment with botulinum toxin on neurogenic blepharospasm, Br. med. J. 240:1857–1859.Google Scholar
  29. Evans, D. M., Williams, R. S., Shone, C. C., Hambleton, P., Melling, J., and Dolly, J. O., 1987, Botulinum type B, its purification, radioiodination and interaction with rat brain synaptosomes, Eur. J. Biochem. 154:409–416.Google Scholar
  30. Evans, D. G. B., 1945, The treatment with anti-toxin of experimental gas gangrene produced in guinea pigs by (a) Clostridium welchii, (b) Clostridium oedematiens and (c) Clostridium septicum, Br. J. Exp. Pathol. 26:104–111.Google Scholar
  31. Fairweather, N. F. and Lyness, V. A., 1986, The complete nucleotide sequence of tetanus toxin, Nucl. Acids. Res. 14:7809–7812.PubMedGoogle Scholar
  32. Fairweather, N. F., Lyness, V. A., and Maskell, D. J., 1987, Immunization of mice against tetanus and fragments of tetanus toxin synthesized in E. coli, Infect. Immun. 55:2541–2545.Google Scholar
  33. Feldman, R. A., Morris, J. G. and Pollard, R. A., 1981, Epidemiologic characteristics of botulism in the United States, in: Biomedical Aspects of Botulism (G. E. Lewis Jr., ed.), Academic Press, New York, pp. 271–284.Google Scholar
  34. Fernie, D. S., Thomson, R. O., Batty, I., and Walker, P. D., 1983, Active and passive immunissation to protect against antibiotic associated caecitis in hamsters, Dev. Biol. 53:325–332.Google Scholar
  35. Florin, I., and Thelestam, M., 1986, ADP-ribosylation in cultured cells treated with Clostridium difficile toxin B, Biochem. Biophys. Res. Commun. 139:64–70.PubMedGoogle Scholar
  36. Gansel, M., Penner, R., and Dreyer, F., 1987, Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals, Pfugers Arch. 409:533–539.Google Scholar
  37. Gonnering, R. S., 1988, Negative antibody response to long-term treatment of facial spasm with botulinum toxin, Am. J. Ophthalmol. 105:313–315.PubMedGoogle Scholar
  38. Granum, P. E., 1982, Inhibition of protein synthesis by a tryptic polypeptide of Clostridium perfringens type A enterotoxin, Biochim. Biophys. Acta 708:6–11.PubMedGoogle Scholar
  39. Granum, P. E., and Whitaker, J. R., 1980, Improved methods for purification of entertoxin from Clostridium perfringens type A, Appl. Env. Microbiol. 39:1120–1122.Google Scholar
  40. Habeeb, A. F. S. A., 1975, Studies on e-prototoxin of Clostridium perfringens type D. Physicochemical and chemical properties of e-prototoxin, Biochim. Biophys. Acta. 412:62–69.PubMedGoogle Scholar
  41. Hambleton, P., Shone, C. C., and Melling, J., 1987, Botulinum Toxin-Structure, action and clinical use, in: Neurotoxins and Their Pharmacological Application (P. Jenner, ed.), New York, Raven Press, pp. 233–260.Google Scholar
  42. Hauschild, A. M. W., 1971, Clostridium perfringens toxin types B, C, D and E, in: Microbial Toxins, Vol. IIa (S. Kadis, T. C. Montie and S.J. Ajl, eds.), Academic Press, New York, pp. 159–188.Google Scholar
  43. Hobbs, B. C., 1979, Clostridium perfringens gastroenteritis, in: Foodborne infections and Intoxication (H. Riemann and F. L. Bryan, eds.), Academic Press, London, pp. 131–171.Google Scholar
  44. Hoch, D. H., Romero-Mira, M., Ehrlich, B. E., Finkelstein, A., DasGupta, B. R., and Simpson, L. L., 1985, Channels formed by botulinum, tetanus and diphtheria toxins in planar lipid bilayers: Relevance to translocation of proteins across membranes, Proc. Natl. Acad. Sci. USA 82:1692–1696.PubMedGoogle Scholar
  45. Horiguchi, Y., Akai, T., and Sakaguchi, G., 1987, Isolation and function of a Clostridium perfringens enterotoxin fragment, Infect. Immun. 55:2912–2915.PubMedGoogle Scholar
  46. Howard, F. M., Flynn, D. M., Bradley, J. M., Noone, P., and Szawatkowski, M., 1977, Outbreak of necrotising enterocolitis caused by Clostridium butyricum. Lancet 2:1099–1102.Google Scholar
  47. Ispolatovskaya, M. V., 1971, Type A Clostridium perfringens toxin, in: Microbiol. Toxins, Vol. IIa (S. Kadis, T. C. Montie, and S. J. Ajl, eds.), Academic Press, New York, pp. 109–158.Google Scholar
  48. Jolivet-Reynaud, C., Cavaillan, J. M., and Alouf, J. E., 1982, Selective cytotoxicity of Clostridium perfringens delta toxin on rabbit leucocytes, Infect. Immun. 38:860–864.PubMedGoogle Scholar
  49. Knight, D. E., 1986, Botulinum toxin types A, B and D inhibit catecholamine secretion from bovine adrenal medullary cells, FEBS Lett. 207:222–226.PubMedGoogle Scholar
  50. Kozaki, S., 1979, Interaction of type A, B and E derivative toxins with synaptosomes of rat brain, Nauny. Schmeideberg’s Arch. Pharmacol. 308:67–70.Google Scholar
  51. Kozaki, S., Kamata, Y., Takafumi, N., Ogasawara, J., and Sakaguchi, G., 1986, The use of monoclonal antibodies to analyse the structure of Clostridium botulinum type E derivative toxin, Infect. Immun. 52:786–791.PubMedGoogle Scholar
  52. Kozaki, S., Ogasawora, J., Shimote, Y., Kamata, Y., and Sakaguchi, G., 1987, Antigenic Structure of Clostridium botulinum type B neurotoxin and its interaction with gangliosides, cerebrosides and free fatty acids, Infect. Immun. 55:3051–3056.PubMedGoogle Scholar
  53. Krivan, H. C., Clark, G. F., Smith, D. F., and Wilkins, T. D., 1986, Cell surface binding of Clostridium difficile enterotoxin: evidence for a glycoprotein containing the sequence Gal α 1–3gal β 1–4G1cNAc, Infect. Immun. 53:573–581.PubMedGoogle Scholar
  54. Lee, J., Elston, J., Vickers, S., Powell, C., Ketley, J., and Hogg, C., 1988, Botulinum toxin therapy for squints, Eye 2:24–28.PubMedGoogle Scholar
  55. Lee, L. and Cherniak, R., 1974, Capsular polysaccharide of Clostridium perfringens Infect. Immun. 9:318–322.Google Scholar
  56. Lewis, G. E., Jr., 1981, Approaches to the prophylaxis immunotherapy and chemotherapy of botulism, in: Biomedical Aspects of Botulism (G. E. Lewis Jr., ed.), Academic Press, New York, pp. 261–270.Google Scholar
  57. Lyerly, D. M., Krivan, H. C., and Wilkins, T. D., 1988, Clostridium difficile: its diseases and toxins, Clin. Microbiol. Rev. 1:1 – 18.PubMedGoogle Scholar
  58. MacLennan, J. D., 1962, The histotoxic clostridial infection of man, Bacteriol.ogy 26:177–174.Google Scholar
  59. Matsuda, M., Makinga, G., and Hirai, T., 1983, Studies on the antibody composition and neutralizing activity of tetanus antitoxin sera from various species of animals in relation to the antigenic substructure of the tetanus toxin molecule, Biken.J. 26:133–143.PubMedGoogle Scholar
  60. Matsuda, M., Ozutsumi, K., Iwashi, M., and Sugimoto, N., 1986, Primary action of Clostridium perfringens type A enterotoxin on Hela and Vero cells in the absence of extracellular calcium: rapid and characteristic changes in membrane permeability, Biochem. Biophys. Res. Commun. 141:704–710.PubMedGoogle Scholar
  61. Matsuoka, I., Syuto, B., Kurihara, K., and Kubo, S., 1987, ADP-ribosylation of specific membrane proteins in pheochromocytoma and primary cultured brain cells by botulinum neurotoxins type C and D, FEBS Lett. 216:295–299.PubMedGoogle Scholar
  62. Mauriello, J. A., 1985, Blepharospasm, Meige syndrome and hemifacial spasm: Treatment with botulinum toxin, Neurology 35:1499–1500.PubMedGoogle Scholar
  63. McClane, B. A., and McDonel, J. C., 1981, Protective effects of osmotic stabilisers on morphological and permeability alterations induced in Vero cells by Clostridium perfringens enterotoxin, Biochim. Biophys. Acta 641:401–409.PubMedGoogle Scholar
  64. McFarland, L. V., and Stamm, W. E., 1986, Review of Clostridium difficile associated diseases, Am. J. Infect. Control 14:99–109.PubMedGoogle Scholar
  65. Melling, J., Hambleton, P., Shone, C. C., 1988, Clostridium botulinum toxins: Nature and preparation for clinical use, Eye 2:16–23.PubMedGoogle Scholar
  66. Midura, T. F., and Arnon, S., 1976, Infant botulism, identification of Clostridium botulinum and its toxin in faeces, Lancet 2:934–936.PubMedGoogle Scholar
  67. Miller, R. M., Woodson, G. E., and Jankovic, J., 1987, Botulinum toxin injection of the vocal fold for spasmodic dysphonia, Arch. Otolary Tngol Head Neck Surg. 113:603–605.Google Scholar
  68. Molgo, J., and Thesleff, S., 1984, Studies on the mode of action of botulinum toxin type A at the frog neuromuscular junction, Brain Res. 279:309–316.Google Scholar
  69. Mollby, R. and Wadstrom, T., 1973, Purification of phospholipase C (alpha toxin) from Clostridium perfringens, Biochim. Biophys. Acta. 321:569–584.PubMedGoogle Scholar
  70. Morris, N. P., Consiglio, E., Hohn, L. D., Habig, W. H., Hardegree, M. C, and Helting, T. B., 1980, Interaction of fragments B and C of tetanus toxin with neural and thyroid membranes and with gangliosides, J. Biol. Chem. 255:6071–6076.PubMedGoogle Scholar
  71. Murayama, S., Syoto, B., Oguma, K., Iida, H., and Kubo, S., 1984, Comparison of Clostridium botulinum toxin types D and C1 in molecular property, antigenicity and binding ability to rat brain synaptosomes, Eur. J. Biochem. 142:487–492.PubMedGoogle Scholar
  72. Nakamura, S., Tanabe, N., Yamakawa, K., and Nishida, S., 1983, Cytotoxin products by Clostridium sordelli strains, Microbiol. Immunol. 27:695–502.Google Scholar
  73. Newbold, K. M., Lord, M. G., and Baglin, T. P., 1987, Role of clostridial organisms in neutropenic enterocolitis, J. Clin. Pathol. 40:471.PubMedGoogle Scholar
  74. Ohashi, Y., and Narumiya, S., 1987, ADP-ribosylation of a MΓ 21,000 membrane protein by type D botulinum toxin, J. Biol. Chem. 262:1430–1433.PubMedGoogle Scholar
  75. Ohishi, I., 1984, Oral toxicities of Clostridium botulinum type A and B toxins from different strains, Infect. Immun. 43:487–490.PubMedGoogle Scholar
  76. Parnas, J., 1976, The effects of Clostridium perfringens beta toxin (type C) on the mobility of intestinal segments in vitro, Abstr. Zentralblat. Bacteriol. Hyg. 234:243–246.Google Scholar
  77. Patrinely, J. R., Whiting, A. S. and Anderson, R. L., 1988, Local side effects of botulinum toxin infections, Adv. Neurol. 49:493–500.PubMedGoogle Scholar
  78. Pedersen, P. V., Hansen, F. H., Halveg, A. B., Christiansen, E. D., Justesten, T., and Hogh, P., 1976, Necrotising enterocolitis in the newborn. Is it gas gangrene of the bowel?, Lancet 2:715–716.PubMedGoogle Scholar
  79. Penner, R., Neher, E., and Dreyer, F., 1986, Intracellularly injected tetanus toxin inhibits exocytosis in bovine adrenal chromaffin cells, Nature 324:76–78.PubMedGoogle Scholar
  80. Phillips, K. D., Brazier, J. S., Levett, P. N., and Willis, A. T., 1985, Clostridia, in: Isolation and Identification of Microorganisms of Medical and Veterinary Importance (C. H. Collins and J. M. Grange, eds.), Academic Press, London, pp. 215–236.Google Scholar
  81. PHLS. CDSC, 1986, Foodborne disease surveillance in England and Wales 1984, Commun. Dis. Rep. 34:3–6.Google Scholar
  82. Pierce, E. J., Davidson, M. D., Parton, R. G., Habig, W. H., and Critchley, D. R., 1986, Characterization of tetanus toxin binding to rat brain membranes, Biochem. J. 236:845–852.PubMedGoogle Scholar
  83. Popoff, M. R., 1987, Purification and Characterization of Clostridium sordelli lethal toxin and cross-reactivity with Clostridium difficile cytotoxin, Infect. Immun. 55:35–43.PubMedGoogle Scholar
  84. Reynolds, D., 1987, The large scale purification of Clostridium pertringens type A enterotoxin and Staphylococcus aureus enterotoxin A M.Phil thesis, Council for National Academic Awards, UK.Google Scholar
  85. Reynolds, D., Tranter, H. S., and Hambleton, P., 1986, Scaled-up production and purification of Clostridium perfringens type A enterotoxin, J. Appl. Bacteriol. 60:517–525.PubMedGoogle Scholar
  86. Richardson, M., and Granum, P. E., 1985, The amino acid sequence of the enterotoxin from Clostridium perfringens type A, FEBS Lett. 182:479–486.PubMedGoogle Scholar
  87. Rogers, T. B., and Snyder, S. H., 1981, High affinity binding of tetanus toxin to mammalian brain membranes, J. Biol. Chem. 256:2402–2407.PubMedGoogle Scholar
  88. Rosener, S., Chatwal, G. S. and Aktories, K., 1987, Botulinum ADP-ribosyltransferase C3 but not neurotoxins CI and D ADP-ribosylates low molecular mass GTP-binding proteins, FEBS Lett. 224:38–42.PubMedGoogle Scholar
  89. Sakurai, J., and Duncan, C. L., 1978, Some properties of Beta-toxin produced by Clostridium perfringens type C, Infect. Immun. 21:678–680.PubMedGoogle Scholar
  90. Sakurai, J., Gujii, Y., and Matsuura, M., 1980, Effect of oxidizing and sulfhydryl group reagents on beta toxin from Clostridium perfringens type C, Microbiol. Immunol. 24:595–601.PubMedGoogle Scholar
  91. Sakurai, J., and Nagahama, M., 1985, Role of one tryptophan residue in the lethal activity of Clostridium perfrigens epsilon toxins, Biochem. Biophys. Res. Commun. 128:760–766.PubMedGoogle Scholar
  92. Sanchez-Prieto, J., Shira, T. S., Evans, D., Ashton, A., Dolly, J. O., and Nicholls, D. G., 1987, Botulinum toxin A blocks glutamate exocytosiis from guinea-pig cerebral cortical synaptosomes, Eur. J. Biochem. 165:675–681.PubMedGoogle Scholar
  93. Schmitt, J. J., and Siegel, L. S., 1986, Purification of type E botulinum neurotoxin by high performance ion exchange chromatography, Anal. Biochem. 156:213–219.Google Scholar
  94. Scott, A. B., 1980, Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery, Ophthalmology 87:1044–1049.PubMedGoogle Scholar
  95. Scott, A. B., 1984, Injection treatment of endocrine orbital myopathy, Doc. Ophthalmol. 58:141–145.PubMedGoogle Scholar
  96. Scott, A. B., 1988, Antitoxin reduces botulinum side effects, Eye 2:29–32.PubMedGoogle Scholar
  97. Scott, A. B., and Kraft, S. P., 1985, Botulinum toxin injection in the management of lateral rectus paresis, Ophthalmol. 92:676–683.Google Scholar
  98. Scott, A. B., Rosenbaum, A. C., and Collins, C. C., 1973, Pharmacological weakening of extraocular muscles, Invest. Ophthalmol. 12:924–927.PubMedGoogle Scholar
  99. Shandera, W. X., Tacket, C. O., and Blake, P. A., 1983, Food poisoning due to Clostridium perfringens in the United States, J. Infect. Dis. 147:167–170.PubMedGoogle Scholar
  100. Shone, C. C., 1987, Clostridium botulinum neurotoxins, their structures and modes of action, in: Natural Toxicants in Foods (D. Watson, ed.), Ellis Horwood Ltd., Chichester, pp. 11–57.Google Scholar
  101. Shone, C. C., Hambleton, P., and Melling, J., 1985, Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments, Eur. J. Biochem. 151:75–85.PubMedGoogle Scholar
  102. Shone, C. C., Hambleton, P., and Melling, J., 1987, A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles, Eur. J. Biochem. 167:175–180.PubMedGoogle Scholar
  103. Simpson, L. L., 1981, The origin, structure and pharmacological activity of botulinum toxin, Pharmacol. Rev. 33:155–188.PubMedGoogle Scholar
  104. Simpson, L. L., 1984, Molecular basis for the pharmacological action of Clostridium botulinum type C2 toxin, J. Pharmacol. Exp. Ther. 230:665–669.PubMedGoogle Scholar
  105. Simpson, L. L., Stiles, B. G., Zepeda, H. H., and Wilkins, T. D., 1987, Molecular Basis for the Pathological Actions of Clostridium perfringens Iota toxin, Infect. Immun. 55:118–122.PubMedGoogle Scholar
  106. Smyth, C. J., 1975, The identification and purification of multiple forms of O-haemolysin (θ toxin) of Clostridium perfringens type A. J. Gen. Microbiol. 87:219–238.PubMedGoogle Scholar
  107. Sterne, M., and Warrack, G. M., 1984, The types of Clostridium perfringens, J. Pathol. Bacteriol. 88:279–283.Google Scholar
  108. Stevens, D. L., Mitten, J., and Henry, C., 1987, Effects of and toxins from Clostridium perfringens on human polymorphonuclear leukocytes, J. Infect. Dis. 156:324–333.PubMedGoogle Scholar
  109. Stiles, B. G., and Wilkins, T. D., 1986, Clostridium perfringens iota toxin: Synergism between two proteins, Toxicon. 24:767–773.PubMedGoogle Scholar
  110. Stringer, M. F., 1985, Clostridium perfringens type A food poisoning, in: Clostridia in Gastrointestinal disease (S. P. Boriello, ed.), CRC, Boca Raton, pp. 117–143.Google Scholar
  111. Sugii, S., Ohishi, I., and Sakaguchi, G., 1977, Intestinal absorption of botulinum toxins of different molecular sizes in rats, Infect. Immun. 17:910–914.Google Scholar
  112. Sugiyama, H., 1980, Clostridium botulinum neurotoxins, Microbiol. Rev. 44:419–448.PubMedGoogle Scholar
  113. Sullivan, N. M., Pellett, M. S., and Wilkins, T. D., 1982, Purification and characterisation of toxins A and B of Clostridium difficile, Infect. Immun. 35:1032–1040.PubMedGoogle Scholar
  114. Tsui, J. K. C., Eisen, A., Stoessl, A. J., Calne, S., and Calne, D. B., 1986, Double-Blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245–247.PubMedGoogle Scholar
  115. Vandekerckhove, J., Schering, B., Barmann, M., and Aktories, K., 1988, Botulinum C2 toxin ADP-ribosylates cytoplasmic β/γ-actin in arginine 177, J. Biol.Chem. 263:696–700.PubMedGoogle Scholar
  116. Walker, P. D., 1985, Pig-Bel, in: Clostridia in gastrointestinal disease, (S. P. Boriello, ed.), CRC, Boca Raton, pp. 93–115.Google Scholar
  117. Wellhoner, H.-H., 1982, Tetanus neurotoxin, Rev. Physiol. Biochem. Pharmacol. 93:1–68.PubMedGoogle Scholar
  118. Williams, R. S., Tse, C.-K.., Dolly, J. O., Hambleton, P., and Melling, J., 1983, Radioiodination of botulinum neurotoxin type A and retention of biological activity and its binding to rat brain synaptosomes, Eur. J. Biochem. 131:437–445.PubMedGoogle Scholar
  119. Willis, A. T., 1969, Clostridia of Wound Infection, Butterworths, London.Google Scholar
  120. Worthington, R. W., and Mulders, M. S. G., 1977, Physical changes in the epsilon prototoxin molecule of Clostridium perfringens during enzymatic activation, 18:549–551.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Clifford C. Shone
    • 1
  • Peter Hambleton
    • 1
  1. 1.Division of BiologicsPublic Health Laboratory Service Centre for Applied Microbiology and ResearchPorton Down, Salisbury, WiltshireEngland

Personalised recommendations